Lehman A F
University of Maryland, Center for Mental Health Services Research, Baltimore 21201, USA.
Psychiatr Q. 1999 Winter;70(4):259-72. doi: 10.1023/a:1022082031007.
The time has come for the development of standards to ensure quality and cost-effective care for the treatment of persons with schizophrenia. Advances in understanding the efficacy of treatments for schizophrenia, the promise of new treatment advances derived from a rapidly evolving neuroscience, pressures to contain health care costs while maintaining or increasing quality, and the growth of advocacy on behalf of persons with schizophrenia are driving this need. The evidence for the efficacy of pharmacotherapies, psychological interventions, family interventions, vocational rehabilitation, and case management and assertive community treatment is substantial, yet many patients do not receive treatments consistent with this evidence. Service systems must do much more to ensure that efficacious treatments are available, that both effectiveness and costs are considered in the allocation of resources, and that evaluative systems are in place to promote on-going quality improvement to provide the best care.
制定标准以确保为精神分裂症患者提供高质量且具成本效益的治疗时机已至。在理解精神分裂症治疗效果方面的进展、快速发展的神经科学带来的新治疗进展的前景、在维持或提高质量的同时控制医疗成本的压力以及代表精神分裂症患者的宣传活动的增加,都推动了这一需求。药物治疗、心理干预、家庭干预、职业康复、病例管理和积极社区治疗的疗效证据确凿,但许多患者并未接受与该证据相符的治疗。服务系统必须做出更多努力,以确保有效的治疗方法可得,在资源分配中同时考虑有效性和成本,并建立评估系统以促进持续的质量改进,从而提供最佳护理。